Nanovibronix Inc (NAOV)

$5.15 -0.75 (-12.71%)
Market Cap 4.48M
Revenue (ttm) 2.56M
Net Income (ttm) -3.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -144.92%
Debt to Equity Ratio 0.00
Volume 534,200
Avg Vol 2,931,776
Day's Range N/A - N/A
Shares Out 759,000.00
Stochastic %K 4%
Beta 1.84
Analysts Strong Buy
Price Target $10.00

Latest News on NAOV

NanoVibronix Regains Nasdaq Compliance

Apr 11, 2025, 8:00 AM EDT - 15 days ago

NanoVibronix Regains Nasdaq Compliance

NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

Apr 1, 2025, 8:00 AM EDT - 25 days ago

NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

Mar 14, 2025, 8:00 AM EDT - 6 weeks ago

Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

NanoVibronix Announces Reverse Stock Split

Mar 12, 2025, 8:00 AM EDT - 6 weeks ago

NanoVibronix Announces Reverse Stock Split

NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.

Feb 14, 2025, 9:43 AM EST - 2 months ago

NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.

NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes

Jan 7, 2025, 8:00 AM EST - 3 months ago

NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes

NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan

Jan 6, 2025, 8:00 AM EST - 3 months ago

NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan

NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement

Dec 11, 2024, 8:00 AM EST - 4 months ago

NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement

NanoVibronix Provides Business Update

Nov 12, 2024, 8:00 AM EST - 5 months ago

NanoVibronix Provides Business Update

NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany

Oct 9, 2024, 8:30 AM EDT - 7 months ago

NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany

NanoVibronix Signs Letter of Intent with Potential New Distributor

Sep 23, 2024, 8:30 AM EDT - 7 months ago

NanoVibronix Signs Letter of Intent with Potential New Distributor

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

Aug 21, 2024, 8:30 AM EDT - 8 months ago

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

May 22, 2024, 8:30 AM EDT - 1 year ago

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Issues Letter to Stockholders

May 16, 2024, 8:30 AM EDT - 1 year ago

NanoVibronix Issues Letter to Stockholders

NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield

May 14, 2024, 8:30 AM EDT - 1 year ago

NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield

NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award

May 1, 2024, 8:00 AM EDT - 1 year ago

NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award

NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024

Apr 24, 2024, 1:00 PM EDT - 1 year ago

NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024

NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

Mar 28, 2024, 8:30 AM EDT - 1 year ago

NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

NanoVibronix Featured in Your Bladder Health Magazine

Dec 6, 2023, 9:00 AM EST - 1 year ago

NanoVibronix Featured in Your Bladder Health Magazine

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

Dec 4, 2023, 9:00 AM EST - 1 year ago

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan

Nov 28, 2023, 9:00 AM EST - 1 year ago

NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan

NanoVibronix Issues Letter to Shareholders

Nov 14, 2023, 8:30 AM EST - 1 year ago

NanoVibronix Issues Letter to Shareholders

NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1

Nov 7, 2023, 8:30 AM EST - 1 year ago

NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1

NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

Sep 27, 2023, 8:00 AM EDT - 1 year ago

NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting

Sep 6, 2023, 8:30 AM EDT - 1 year ago

NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting

NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aug 30, 2023, 2:29 PM EDT - 1 year ago

NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

NanoVibronix Cites Positive Results from Independent Testing of UroShield

Aug 30, 2023, 8:30 AM EDT - 1 year ago

NanoVibronix Cites Positive Results from Independent Testing of UroShield

NanoVibronix Responds to CMS' Determination for PainShield

Aug 29, 2023, 4:05 PM EDT - 1 year ago

NanoVibronix Responds to CMS' Determination for PainShield

NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

Aug 28, 2023, 8:30 AM EDT - 1 year ago

NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus

Aug 23, 2023, 8:45 AM EDT - 1 year ago

NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus

NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard

Jun 14, 2023, 8:30 AM EDT - 2 years ago

NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard

NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)

Mar 28, 2023, 8:30 AM EDT - 2 years ago

NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra

Mar 21, 2023, 8:30 AM EDT - 2 years ago

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra

NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury

Mar 14, 2023, 9:15 AM EDT - 2 years ago

NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury

NanoVibronix to Launch Rental Program for PainShield and UroShield

Feb 22, 2023, 8:30 AM EST - 2 years ago

NanoVibronix to Launch Rental Program for PainShield and UroShield

NanoVibronix Provides Update on Expanding Access to PainShield

Jan 18, 2023, 8:30 AM EST - 2 years ago

NanoVibronix Provides Update on Expanding Access to PainShield

NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

Dec 15, 2022, 4:05 PM EST - 2 years ago

NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

NanoVibronix Announces Partnership with Peak Medical, Ltd.

Dec 13, 2022, 8:30 AM EST - 2 years ago

NanoVibronix Announces Partnership with Peak Medical, Ltd.

NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 1, 2022, 2:06 PM EST - 2 years ago

NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 29, 2022, 8:07 AM EST - 2 years ago

NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Nov 28, 2022, 3:18 PM EST - 2 years ago

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

NanoVibronix Announces Interim Results of Clinical Study for UroShield

Nov 16, 2022, 8:30 AM EST - 2 years ago

NanoVibronix Announces Interim Results of Clinical Study for UroShield

NanoVibronix Provides Business Update in Letter to Shareholders

Nov 15, 2022, 8:33 AM EST - 2 years ago

NanoVibronix Provides Business Update in Letter to Shareholders

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

Oct 19, 2022, 8:30 AM EDT - 2 years ago

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract

Sep 23, 2022, 8:30 AM EDT - 2 years ago

NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract

NanoVibronix Sets Date for Annual Shareholder Meeting

Sep 14, 2022, 4:05 PM EDT - 2 years ago

NanoVibronix Sets Date for Annual Shareholder Meeting

NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

Sep 14, 2022, 9:25 AM EDT - 2 years ago

NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

Sep 2, 2022, 4:30 PM EDT - 2 years ago

NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

NanoVibronix Announces Webinar Series to Promote UroShield

Jul 12, 2022, 8:30 AM EDT - 3 years ago

NanoVibronix Announces Webinar Series to Promote UroShield

NanoVibronix Strengthening Supply Chain Increasing Efficiency and Scalability

Jun 29, 2022, 8:30 AM EDT - 3 years ago

NanoVibronix Strengthening Supply Chain Increasing Efficiency and Scalability